CY1124717T1 - Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων - Google Patents

Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων

Info

Publication number
CY1124717T1
CY1124717T1 CY20211100943T CY211100943T CY1124717T1 CY 1124717 T1 CY1124717 T1 CY 1124717T1 CY 20211100943 T CY20211100943 T CY 20211100943T CY 211100943 T CY211100943 T CY 211100943T CY 1124717 T1 CY1124717 T1 CY 1124717T1
Authority
CY
Cyprus
Prior art keywords
kits
cells
provides
expansion
methods
Prior art date
Application number
CY20211100943T
Other languages
Greek (el)
English (en)
Inventor
Lothar Germeroth
Christian STEMBERGER
Original Assignee
Juno Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Gmbh filed Critical Juno Therapeutics Gmbh
Publication of CY1124717T1 publication Critical patent/CY1124717T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
    • C12N2537/10—Cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Sustainable Development (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Computer Hardware Design (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physics & Mathematics (AREA)
CY20211100943T 2014-04-16 2021-11-02 Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων CY1124717T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980506P 2014-04-16 2014-04-16
PCT/EP2015/058339 WO2015158868A2 (en) 2014-04-16 2015-04-16 Methods, kits and apparatus for expanding a population of cells

Publications (1)

Publication Number Publication Date
CY1124717T1 true CY1124717T1 (el) 2022-07-22

Family

ID=53052805

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100943T CY1124717T1 (el) 2014-04-16 2021-11-02 Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων

Country Status (27)

Country Link
US (2) US11274278B2 (https=)
EP (2) EP3988920A1 (https=)
JP (4) JP6696969B2 (https=)
KR (2) KR102714469B1 (https=)
CN (3) CN106414724A (https=)
AU (2) AU2015248786B2 (https=)
BR (1) BR112016024072B1 (https=)
CA (2) CA3176848A1 (https=)
CY (1) CY1124717T1 (https=)
DK (1) DK3132247T3 (https=)
ES (1) ES2892927T3 (https=)
HR (1) HRP20211430T1 (https=)
HU (1) HUE056852T2 (https=)
IL (3) IL280738B (https=)
LT (1) LT3132247T (https=)
MX (2) MX380519B (https=)
MY (1) MY184699A (https=)
PH (2) PH12016502017A1 (https=)
PL (1) PL3132247T3 (https=)
PT (1) PT3132247T (https=)
RS (1) RS62471B1 (https=)
RU (2) RU2735640C9 (https=)
SA (3) SA521421882B1 (https=)
SG (2) SG10201808491UA (https=)
SI (1) SI3132247T1 (https=)
SM (1) SMT202100600T1 (https=)
WO (1) WO2015158868A2 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
BR112016024072B1 (pt) 2014-04-16 2021-02-09 Juno Therapeutics Gmbh método in vitro de estimular uma população de células
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
JP7194020B2 (ja) 2015-10-22 2022-12-21 ジュノ セラピューティクス ゲーエムベーハー 細胞の培養方法ならびにそのためのキットおよび装置
US11248238B2 (en) * 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
SG11201803330WA (en) * 2015-10-22 2018-05-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN107129988A (zh) * 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用
WO2017210607A1 (en) * 2016-06-02 2017-12-07 Klotho Therapeutics, Inc. Therapeutic recombinant klotho proteins and compositions and methods involving the same
US20240018268A1 (en) 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
AU2017370644A1 (en) * 2016-12-05 2019-06-13 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
US12234441B2 (en) * 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) * 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) * 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7339160B2 (ja) * 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
JP7433230B2 (ja) 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
MX2020006297A (es) * 2017-12-15 2020-12-07 Aleta Biotherapeutics Inc Variantes de cd19.
CN107904278B (zh) * 2017-12-25 2021-07-20 北昊干细胞与再生医学研究院有限公司 检测药物对细胞增殖影响的方法
US11149244B2 (en) * 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
EP3790958A1 (en) * 2018-05-08 2021-03-17 Life Technologies Corporation Compositions and methods for culturing and expanding cells
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
CN113056486B (zh) 2018-09-11 2025-06-17 德国肿瘤研究中心 改善的抗flt3抗原结合蛋白
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
SG11202102986XA (en) * 2018-09-24 2021-04-29 Southwest Res Inst Three-dimensional bioreactors
EP3874024A1 (en) * 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
KR20200132147A (ko) * 2019-05-15 2020-11-25 의료법인 성광의료재단 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법
WO2020241999A1 (ko) * 2019-05-24 2020-12-03 고려대학교 세종산학협력단 스위치 성 부착반응을 이용한 친화 분리 시스템 및 방법
MX2021015125A (es) * 2019-06-07 2022-04-06 Juno Therapeutics Inc Cultivo automatizado de celulas t.
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
CN115916817A (zh) 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
WO2021152178A1 (en) 2020-01-31 2021-08-05 Cell.Copedia GmbH Methods of isolating a biological entity
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
IL295384B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
CN117957313A (zh) 2021-07-19 2024-04-30 修复免疫股份有限公司 从多能干细胞生产免疫细胞群的方法
CN116286659A (zh) * 2021-10-25 2023-06-23 黄�俊 多聚体在car表达细胞检测和细胞制备中的应用
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
KR20260005874A (ko) 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 전신 자가면역 질환을 치료하기 위한 세포 요법
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
CN121464348A (zh) 2023-05-23 2026-02-03 朱诺治疗学股份有限公司 T细胞的激活标记物和评估t细胞激活的方法
CN117448255B (zh) * 2023-09-28 2024-12-31 深圳市龙华区人民医院 S2饲养细胞、制备方法及其应用
WO2025109111A1 (en) * 2023-11-22 2025-05-30 Immudex Aps Immune cell activating multimers
KR102824339B1 (ko) * 2024-07-01 2025-06-26 현대자동차주식회사 배터리 제어 장치 및 그 방법
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
WO1986002077A1 (en) 1984-10-02 1986-04-10 Meade Harry M Production of streptavidin-like polypeptides
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
EP0700430B1 (en) 1993-06-04 2005-04-20 The United States of America as Represented by the Secretary of the Navy Methods for selectively stimulating proliferation of t cells
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
CA2211951A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
AU6701498A (en) 1997-03-14 1998-09-29 Trustees Of Boston University Multiflavor streptavidin
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
WO2000043551A1 (en) 1999-01-26 2000-07-27 Cornell Research Foundation, Inc. Determining viral load in double negative t cells
DK1149114T3 (da) * 1999-02-03 2014-06-23 Amgen Inc Polypeptider, der er involveret ved et immunrespons
BR0009403A (pt) 1999-02-04 2001-11-27 Technion Res & Dev Foundation Método de expansão/conservação das células detronco hemopoiéticas indiferenciadas ou dascélulas progenitoras, método de preparação deum meio condicionado de célula estomacal útil naexpansão/conservação das células de troncohemopoiéticas indiferenciadas ou das célulasprogenitoras, método de transplante de célulasde tronco hemopoiéticas indiferenciadas ou decélulas progenitoras em um recipiente, tampão debiorreator e biorreator
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
ATE370159T1 (de) 2002-03-01 2007-09-15 Volker A Erdmann Streptavidin-bindungspeptid
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
WO2003090781A1 (en) 2002-04-23 2003-11-06 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
CA2500392C (en) 2002-09-27 2012-11-27 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
CA2565581C (en) 2003-05-02 2014-07-08 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
EP1623017B1 (en) 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
US20080050795A1 (en) 2003-11-20 2008-02-28 Biosensor Applications Sweden Ab Mixture Of At Least Two Different Antibodies Specific For Predetermined Antigens And Use Of The Mixture
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7776583B2 (en) 2004-06-03 2010-08-17 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
US20110098184A1 (en) 2004-10-15 2011-04-28 Day Anthony G Competitve differntial screeing
WO2006058226A2 (en) * 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US7704708B2 (en) * 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US20090208471A1 (en) 2006-04-07 2009-08-20 Yun Theodore J Isolation and Use of Human Regulatory T Cells
US20070238169A1 (en) * 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
DK2091965T3 (da) 2006-10-17 2013-08-05 Oncotherapy Science Inc Peptidvacciner mod cancere, der udtrykker MPHOSPH1- eller DEPDC1-polypeptider
JP5557450B2 (ja) 2006-11-02 2014-07-23 協和メデックス株式会社 測定対象成分の免疫測定法
AU2007353319A1 (en) 2006-11-15 2008-11-20 Invitrogen Dynal As Methods for reversibly binding a biotin compound to a support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
WO2008118476A2 (en) * 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
DK2193199T3 (da) 2007-08-20 2014-01-13 Nextera As Pvii fag-display
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
CA2713462C (en) 2008-01-29 2020-04-14 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
US20120214187A1 (en) * 2009-11-02 2012-08-23 Ffina Biolutions, Llc Method for Enhancing the Sensitivity of Antibody Based Assays
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
EP2601521B1 (en) 2010-08-06 2018-05-02 Ludwig-Maximilians-Universität München Identification of t cell target antigens
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
TR201811128T4 (tr) * 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.
WO2013038272A2 (en) 2011-09-13 2013-03-21 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
RU2746407C1 (ru) * 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
UA114108C2 (uk) * 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
AU2013289979A1 (en) 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced T cells for administration
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2014076277A1 (en) 2012-11-16 2014-05-22 Iba Gmbh Streptavidin muteins and methods of using them
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
BR112016024072B1 (pt) 2014-04-16 2021-02-09 Juno Therapeutics Gmbh método in vitro de estimular uma população de células
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
NZ725201A (en) 2014-04-25 2018-05-25 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
CA2945414C (en) * 2014-04-30 2023-05-09 Iba Gmbh Method of isolating a target cell
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
JP7194020B2 (ja) 2015-10-22 2022-12-21 ジュノ セラピューティクス ゲーエムベーハー 細胞の培養方法ならびにそのためのキットおよび装置
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
SG11201803330WA (en) 2015-10-22 2018-05-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same

Also Published As

Publication number Publication date
IL280738A (en) 2021-03-25
AU2022200527A1 (en) 2022-02-17
PT3132247T (pt) 2021-11-03
EP3132247A2 (en) 2017-02-22
NZ763587A (en) 2021-11-26
IL293587B1 (en) 2024-10-01
SG11201608557UA (en) 2016-11-29
SI3132247T1 (sl) 2021-12-31
KR102459384B1 (ko) 2022-10-26
AU2022200527B2 (en) 2025-03-27
JP2023062124A (ja) 2023-05-02
JP2017513524A (ja) 2017-06-01
JP7762499B2 (ja) 2025-10-30
PH12016502017B1 (en) 2017-01-09
KR102714469B1 (ko) 2024-10-11
DK3132247T3 (da) 2021-10-11
RU2020133435A (ru) 2020-12-01
CN111961647A (zh) 2020-11-20
SA521421882B1 (ar) 2023-11-19
JP6696969B2 (ja) 2020-05-20
WO2015158868A3 (en) 2016-01-28
CA2945889C (en) 2024-01-09
US20170037368A1 (en) 2017-02-09
PH12020551028A1 (en) 2021-06-07
CN116656605A (zh) 2023-08-29
RS62471B1 (sr) 2021-11-30
SMT202100600T1 (it) 2021-11-12
AU2022200527B9 (en) 2025-05-08
SA520412247B1 (ar) 2023-12-05
SA516380090B1 (ar) 2021-10-21
LT3132247T (lt) 2021-12-10
US11274278B2 (en) 2022-03-15
NZ763583A (en) 2021-10-29
JP2025060756A (ja) 2025-04-10
EP3988920A1 (en) 2022-04-27
HUE056852T2 (hu) 2022-03-28
CA2945889A1 (en) 2015-10-22
KR20220150988A (ko) 2022-11-11
PL3132247T3 (pl) 2022-01-03
CN106414724A (zh) 2017-02-15
NZ763585A (en) 2021-10-29
WO2015158868A2 (en) 2015-10-22
IL293587A (en) 2022-08-01
PH12016502017A1 (en) 2017-01-09
SG10201808491UA (en) 2018-11-29
MX380519B (es) 2025-03-12
CA3176848A1 (en) 2015-10-22
MX2016013493A (es) 2017-05-10
RU2016144724A (ru) 2018-05-18
BR112016024072A2 (pt) 2017-10-10
IL280738B (en) 2022-07-01
KR20170003932A (ko) 2017-01-10
NZ725213A (en) 2021-10-29
IL293587B2 (en) 2025-02-01
ES2892927T3 (es) 2022-02-07
JP2020124210A (ja) 2020-08-20
EP3132247B1 (en) 2021-08-18
RU2735640C9 (ru) 2021-02-08
MX2020014089A (es) 2021-07-21
RU2016144724A3 (https=) 2018-12-12
MY184699A (en) 2021-04-18
AU2015248786A1 (en) 2016-11-03
IL248360B (en) 2021-02-28
BR112016024072B1 (pt) 2021-02-09
RU2735640C2 (ru) 2020-11-05
AU2015248786B2 (en) 2021-11-04
HRP20211430T1 (hr) 2021-12-10
IL248360A0 (en) 2016-11-30
US20220195388A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
CY1124717T1 (el) Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων
CY1123220T1 (el) Πρωτεϊνες συνδεσης anti-lag-3
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
BR112017022329A2 (pt) métodos para detectar aglutinação e composições para uso na prática do mesmo
CL2017002604A1 (es) Sondas duales silenciadoras
CL2016001867A1 (es) Sistema y dispositivo para la generación de alto rendimiento de gotitas y métodos de uso combinatorios.
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
CA2873099C (en) Aptamer-based multiplexed assays
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EP4300100A3 (en) Reagent storage in an assay device
SA518400078B1 (ar) مصفوفة مولد ضد
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
BR112014018995A2 (pt) Sistemas para executar ensaio automatizado
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
AU2013252445A8 (en) Assays, methods and apparatus for assessing RNA disruption
MX2017001134A (es) Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana.
TR201907737T4 (tr) Test numunesi desteği ve çarpışma testi aparatı ve destek kullanılarak yapısal elemanın çarpışma testi yöntemi.
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
CY1123180T1 (el) Συστημα ανιχνευσης που αξιοποιει αλυσιδωτη αντιδραση πολυμερασης
BR112017008393A2 (pt) aparelho e sistema para amplificação de ácido nucleico
BR112017002575A2 (pt) método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo
MX2021015057A (es) Anticuerpos anti-talen y usos de los mismos.